Glatiramer acetate to treat multiple sclerosis during pregnancy and lactation: a safety evaluation

Bibliography

• Birk K, Rudick R. Pregnancy and multiple sclerosis. Arch Neurol 1986;43:719-26
   PubMed Web of Science ®Google Scholar
• Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998;339:285-91
   PubMed Web of Science ®Google Scholar
• Karp I, Manganas A, Sylvestre MP, et al. Does pregnancy alter the long-term course of multiple sclerosis? Ann Epidemiol 2014;24:504-8
   PubMed Web of Science ®Google Scholar
• Noyes K, Weinstock-Guttman B. Impact of diagnosis and early treatment on the course of multiple sclerosis. Am J Manag Care 2013;19(17 Suppl):s321-31
   PubMed Web of Science ®Google Scholar
• Correale J, Ysrraelit MC, Fiol MP. Benign multiple sclerosis: does it exist? Curr Neurol Neurosci Rep 2012;12:601-9
   PubMed Web of Science ®Google Scholar
• Fragoso YD. Is it correct for a woman with multiple sclerosis to forgo medication because she may become pregnant? Arq Neuro-Psiquiatr 2013;71:826-7
   PubMed Web of Science ®Google Scholar
• Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler 2011;17:423-30
   PubMed Web of Science ®Google Scholar
• Fragoso YD, Adoni T, Alves-Leon SV, et al. Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review. CNS Drugs 2013;27:955-61
   PubMed Web of Science ®Google Scholar
• Hughes SE, Spelman T, Gray OM, et al. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler 2014;20:739-46
   PubMed Web of Science ®Google Scholar
• Haghikia A, Langer-Gould A, Rellensmann G, et al. Natalizumab Use during the third trimester of pregnancy. JAMA Neurol 2014;71(7):891-5
   PubMed Web of Science ®Google Scholar
• Teitelbaum D, Meshorer A, Hirshfeld T, et al. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971;1:242-8
   PubMed Web of Science ®Google Scholar
• Scott LJ. Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. CNS Drugs 2013;27:971-88
   PubMed Web of Science ®Google Scholar
• Aharoni R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun Rev 2013;12:543-53
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA) pregnancy categories. Available from: http://depts.washington.edu/druginfo/Formulary/Pregnancy.pdf [Last accessed on 28 June 2014]
   Google Scholar
• Sannerstedt R, Lundborg P, Danielsson BR, et al. Drugs during pregnancy: an issue of risk classification and information to prescribers. Drug Saf 1996;14:69-77
   PubMed Web of Science ®Google Scholar
• Coyle PK, Johnson K, Pardo L, Stark Y. Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone 1). In: Proceedings of the 55th Annual Meeting of the American Academy of Neurology; 29 March–5 April 2003; Honolulu, Hawaii, USA; Neurology 2003;60(5)(Suppl 1):A60 [abstract]
   Google Scholar
• De Las Heras V, De Andrés C, Téllez N, Tintoré M; EMPATIE Study Group. Pregnancy in multiple sclerosis patients treated with immunomodulators prior to or during part of the pregnancy: a descriptive study in the Spanish population. Mult Scler 2007;13:981-4
   PubMed Web of Science ®Google Scholar
• Lu E, Zhu F, Zhao Y, et al. Birth outcomes of pregnancies fathered by men with multiple sclerosis. Mult Scler 2014. [Epub ahead of print]
   Google Scholar
• Langer-Gould A, Beaber BE. Effects of pregnancy and breastfeeding on the multiple sclerosis disease course. Clin Immunol 2013;149:244-50
   PubMed Web of Science ®Google Scholar
• Pakpoor J, Disanto G, Lacey MV, et al. Breastfeeding and multiple sclerosis relapses: a meta-analysis. J Neurol 2012;259:2246-8
   PubMed Web of Science ®Google Scholar
• Portaccio E, Ghezzi A, Hakiki B, et al. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. J Neurol Neurosurg Psychiatry 2014;85(8):845-50
   PubMed Web of Science ®Google Scholar
• Wundes A, Pebdani RN, Amtmann D. What do healthcare providers advise women with multiple sclerosis regarding pregnancy? Mult Scler Int 2014;2014:819216
   PubMedGoogle Scholar
• Coyle PK, Christie S, Fodor P, et al. Multiple sclerosis gender issues: clinical practices of women neurologists. Mult Scler 2004;10:582-8
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Neuhaus O, Hohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf 2001;24:979-90
   PubMed Web of Science ®Google Scholar
• Available from: http://www.drugs.com/breastfeeding/glatiramer.html [Last accessed on 28 June 2014]
   Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45(7):1268-76
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998;50(3):701-8
   PubMed Web of Science ®Google Scholar
• Fragoso YD, Finkelsztejn A, Comini-Frota ER, et al. Pregnancy and multiple sclerosis: the initial results from a Brazilian database. Arq Neuro-Psiquiatr 2009;67:657-60
   PubMed Web of Science ®Google Scholar
• Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler 2009;15:1037-42
   PubMed Web of Science ®Google Scholar
• Fernández Liguori N, Klajn D, Acion L, et al. Epidemiological characteristics of pregnancy, delivery, and birth outcome in women with multiple sclerosis in Argentina (EMEMAR study). Mult Scler 2009;15:555-62
   PubMed Web of Science ®Google Scholar
• Salminen HJ, Leggett H, Boggild M. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J Neurol 2010;257:2020-3
   PubMed Web of Science ®Google Scholar
• Fragoso YD, Finkelsztejn A, Kaimen-Maciel DR, et al. Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series. CNS Drugs 2010;24:969-76
   PubMed Web of Science ®Google Scholar
• Hellwig K, Gold R. Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis. J Neurol 2011;258:502-3
   PubMed Web of Science ®Google Scholar
• Hellwig K, Haghikia A, Rockhoff M, Gold R. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord 2012;5:247-53
   PubMed Web of Science ®Google Scholar
• Lu E, Dahlgren L, Sadovnick A, et al. Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs. Mult Scler 2012;18:460-7
   PubMed Web of Science ®Google Scholar
• Giannini M, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol 2012;12:124
   PubMed Web of Science ®Google Scholar
• Fragoso YD, Boggild M, Macias-Islas MA, et al. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. Clin Neurol Neurosurg 2013;115:154-9
   PubMed Web of Science ®Google Scholar
• Vanya M, Nyari T, Bencsik K, Bartfai G. Pregnancy and perinatal outcomes among women with multiple sclerosis: a retrospective case-controlled study in South Hungary. J Matern Fetal Neonatal Med 2014;27:577-81
   PubMed Web of Science ®Google Scholar
• Pecori C, Giannini M, Portaccio E, et al. Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurol 2014;14:114
   PubMed Web of Science ®Google Scholar